CLAIMS

1. Use of a PPARα agonist, metformin and a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical formulation for decreasing serum triglycerides.

2. Use of a PPARα agonist, metformin and a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical formulation for the treatment of metabolic syndrome.

3. Use of a PPARα agonist, metformin and a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical formulation for the treatment of obesity.

4. The use according to one of claims 1 to 3, wherein the PPARα agonist is a fibrate selected from the group consisting of gemfibrozil, fenofibrate, bezafibrate, clofibrate and ciprofibrate, a fibric acid derivative or a pharmaceutically acceptable salt or ester of said fibric acid derivative.

5. The use according to claim 4, wherein the fibrate is fenofibrate, fenofibric acid or a pharmaceutically acceptable salt or ester of fenofibric acid.

6. The use according to one of claims 1 to 5, wherein the effective dosage of the PPARα agonist is in the range of about 10 to about 3000 mg per day.

7. The use according to one of claims 1 to 6, wherein the effective dosage of metformin is in the range of about 10 to about 3000 mg per day.

8. The use according to one of claims 1 to 7, wherein the PPARα agonist and metformin are administered simultaneously.

9. The use according to one of claims 1 to 7, wherein the PPARα agonist and metformin are administered sequentially.

10. Use of a PPARα agonist and metformin for the manufacture of a kit for decreasing serum triglycerides, for the treatment of metabolic syndrome or for the treatment of obesity, the kit comprising two separate compositions, the first comprising the PPARα agonist and the second comprising metformin or a pharmaceutically acceptable salt thereof.

11. A method of decreasing serum triglycerides, of treating the metabolic syndrome or of treating obesity comprising co-administering to a patient in need thereof an effective dosage of a PPARα agonist and metformin.

12. The method according to claim 11, wherein the PPARα agonist is a fibrate selected from the group consisting of gemfibrozil, fenofibrate, bezafibrate, clofibrate and ciprofibrate, a fibric acid derivative or a pharmaceutically acceptable salt or ester of said fibric acid derivative.

13. The method according to claim 12, wherein the fibrate is fenofibrate, fenofibric acid or a pharmaceutically acceptable salt or ester of fenofibric acid.

14. The method according to one of claims 11 to 13, wherein the effective dosage of the PPARα agonist is in the range of about 10 to about 3000 mg per day.

15. The method according to one of claims 11 to 14, wherein the effective dosage of metformin is in the range of about 10 to about 3000 mg per day.

16. The method according to one of claims 11 to 15, wherein the PPARα agonist and metformin are administered simultaneously.

17. The method according to one of claims 11 to 15, wherein the PPARα agonist and metformin are administered sequentially.